# A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

> **NCT05970432** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** TQH2722 injection 300mg-150mg
- **DRUG:** TQH2722 injection 600mg-300mg
- **DRUG:** TQH2722 injection 900mg-450mg
- **DRUG:** TQH2722 injection matching Placebo

## Key facts

- **NCT ID:** NCT05970432
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-19
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970432, "A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05970432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*